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Abstract
Technology advances have promoted gene-based sequencing studies with the aim of identifying rare mutations
responsible for complex diseases. A complication in these types of association studies is that the vast majority of non-
synonymous mutations are believed to be neutral to phenotypes. It is thus critical to distinguish potential causative variants
from neutral variation before performing association tests. In this study, we used existing predicting algorithms to predict
functional amino acid substitutions, and incorporated that information into association tests. Using simulations, we
comprehensively studied the effects of several influential factors, including the sensitivity and specificity of functional
variant predictions, number of variants, and proportion of causative variants, on the performance of association tests. Our
results showed that incorporating information regarding functional variants obtained from existing prediction algorithms
improves statistical power under certain conditions, particularly when the proportion of causative variants is moderate. The
application of the proposed tests to a real sequencing study confirms our conclusions. Our work may help investigators who
are planning to pursue gene-based sequencing studies.
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Introduction
Genotyping based genetic association analyses, which are
dependent on indirect linkage disequilibrium (LD) mapping, rely
on the common disease-common variants (CDCV) hypothesis.
The CDCV hypothesis assumes that genetic variants responsible
for complex diseases are common in frequency in the human
population [1,2,3]. Despite successful utilization of genome-wide
association studies (GWAS) to identify susceptible common
variants for a variety of complex diseases [4], only a modest
fraction of phenotypic variation has been accounted for by the
identified variants. Therefore, it is reasonable to propose that there
are limitations to the CDCV hypothesis, and to consider the
alternative common disease-rare variants (CDRV) hypothesis as a
complement [5,6,7,8]. In the CDRV hypothesis, phenotypic
variation is attributable to multiple variants, each with a low
frequency and a small to moderate marginal effect.
Advances in next-generation sequencing technologies
[9,10,11,12] and the recently launched ‘1000 Genomes Project’
[13] have enhanced our ability to discover rare variants. While
knowledge regarding rare variants is becoming increasingly
detailed, statistical analyses of rare variants present a number of
challenges. Ordinary variant-by-variant methods that are suited
for analyses of common variants have a limited capacity to detect
rare variants due to their extremely low frequency. Additionally,
the high number of tests to be examined reduces statistical power
dramatically when correction for multiple testing is taken into
account. To circumvent these problems, the analytical strategy of
grouping variants has been suggested [14,15,16,17]. Grouping
strategy uses genomic regions (e.g. genes, that contain a set of
variants) as the unit of analysis. This strategy is advantageous
because it enhances the mutation signal as well as reduces the
number of tests. Nonetheless, as not all nonsynonymous rare
variants within genes are causative, grouping all of them regardless
of their functional impact may have the undesirable effect of
producing an unsatisfactory signal-to-noise ratio. Therefore,
successful use of the grouping strategy is critically dependent
upon the ability to distinguish potential causative variants from
background population variation prior to analysis.
The potential functional importance of non-synonymous
variants, or of the resulting amino acid substitutions, can be
studied from a biological perspective. The functional impact of
amino acid substitutions can be predicted by specialized
algorithms that take into account context information for the
specific protein being analyzed [18,19,20,21,22,23,24,25,26,27].
By incorporating information obtained from predicting algorithms
into association analyses, potentially causative variants can be
preliminarily distinguished from background population variation,
thereby improving the efficiency of these analyses.
In this study, we test the association between non-synonymous
variants in gene coding regions and disease. In order to determine
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13857the relative importance of variants in terms of phenotypic effect,
prediction algorithms were extensively utilized to identify
functional amino acid substitutions, and we incorporated results
from these prediction algorithms into association tests. We aimed
to evaluate whether, and to what extent, incorporation of results
from these prediction algorithms can improve statistical power for
detecting disease associated rare variants. We also evaluated the
performance of tests by analyzing a real sequence dataset to
demonstrate the utility of the proposed tests.
Methods
In figure 1, we outline the steps that we follow to simulate data
and perform association test. In what is followed at this section, we
will describe each of these steps in details.
Modeling site-frequency spectrum
By focusing on the European population, we simulate the full
range frequencies of sequence data using a four-parameter
demographic model [14,28]. In this model, the shape of the
European population history is assumed to start from a constant
ancestral population, followed by a population bottleneck with a
reduction in effective size, and then by an exponential expansion
until to modern population. The four parameters involved are the
constant ancestral population size N1, the bottleneck population
size Nb, the duration of time T after the bottleneck (measured by
generation), and the population growth rate c after the bottleneck.
In Appendix S1, we outline the formulation of the demographic
model and the data we use to estimate its parameters.
Simulating genotypes
Using the inferred demographic model, we simulate the full
range allele frequencies of sequence data of a gene coding region
to mimic a gene-wise sequencing study. We simulate a gene with
L=1,500 nucleotides by assuming an average length of 500 amino
acids for proteins [14]. In accordance with a previous estimation
[29], one third of the simulated variants are assumed to be
synonymous mutations, which does not affect gene expression and
are not included in our analysis. Of the remaining non-
synonymous mutations, previous studies have indicated that the
majority are actually background population variation [30,31].
We thus set the proportion of causative variants f=0.2 [31].
However, we also evaluate two other proportions (0.5 and 0.8) for
comparison.
Simulating the pool of quantitatively phenotyped
individuals
Though we test association with a case/control study design,
individuals are sampled from the two tails of the distribution of a
quantitatively phenotyped population. This extreme sampling
scheme is advantageous because enlarging the size of phenotyped
pool alone could improve statistical power to detect the association;
this approach has been widely adopted by several well-established
sequencing-based association studies [14,32,33,34]. As a baseline,
we generate a pool with 50,000 quantitatively phenotyped
individuals. Causative variants are randomly selected, and they
affect the phenotype in a cumulative matter in that individuals
carrying more causative mutations have larger shifts of the
Figure 1. Flow chart of simulation studies.
doi:10.1371/journal.pone.0013857.g001
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causative score xj~
P Ln
l~1
Ilgjl, where Ln is the number of non-
synonymous rare variants; Il (1 or 0) is the indicator of causative
variant, and gjl (0, 1, or 2) is the genotype score at the variant. The
relationship between the phenotype and genotype is modeled by a
linear regression equation
yj~mzbxjzej,
where m is the grand phenotypic mean; ej is the random error which
follows a normal distribution with zero mean. The coefficient b is
determined by the locus heritability h
2, which is defined as
h2~
b
2 var(x)
b
2 var(x)zvar(e)
:
As a baseline, we set h
2 to be equal to 0.5%.
When common variants are selected as causative, they affect the
phenotype individually by the above linear regression equation. Of
the total 0.5% locus heritability, 10% is attributable to common
variants.
Sampling extreme phenotyped individuals for
sequencing
After the pool of phenotyped individuals is generated, we select
individuals with lowest and highest phenotypes for sequencing. As
a baseline, we select nu=1,000 individuals with the lowest
phenotypes and label them as control subjects. Similarly, we
select nc=1,000 individuals with the highest phenotypes and label
them as case subjects.
Predicting the functional impact of non-synonymous
SNPs
Since not all non-synonymous mutations are causative, we add a
step to differentiate functional variants from background neutral
variation based on the specific amino acid substitutions using
existing prediction algorithms, e.g., PolyPhen [19] and SIFT [21].
We assume that functional variants are all causative. The
information obtained from predicting algorithms can be used to
generate qualitative (e.g., the variant results in damaged protein) or
quantitative (e.g., a continuous score reflecting the degree of impact
on protein function) measures. We assume that both measures are
available. For simplicity, we take an indicator O as the qualitative
measure of being functional (O=1) or not (O=0), and we take a
probability p (0ƒpƒ1) as the quantitative measure, though the
bounds 0 and 1 on the range of measure are not required.
The performance of a specific predicting algorithm is measured
by its sensitivity, e.g., the probability of correctly identifying a truly
functional mutation, and specificity, e.g., the probability of
incorrectly classifying a non-functional mutation as a functional
one. Assume that the sensitivity and the specificity are b and a.
Specifically, we have P(O~1DI~1)~b, and P(O~1DI~0)~a.
Thus, O is simulated from a Bernoulli distribution Ber(b) for
causative variants, and from Ber(a) for neutral variants. Given
O=1 or 0, we simulate quantitative measure p from the Uniform
distribution U(a, 1) or U(0, a), where a is the threshold to declare a
causative variant. We set a=0.9.
Estimations of sensitivity and specificity are available for most
predicting algorithms [27]. The sensitivity ranges from 0.69 to
0.88, and specificity from 0.08 to 0.2. In this study, we set them to
average values, e.g., sensitivity to 0.8 and specificity to 0.15, unless
otherwise specified.
Testing association
Individual rare variants, e.g., MAF,1%, provide limited
information to detect the association, and an effective approach
to analyze them is to group them together [15,16]. The first step
for analyzing a group of rare variants involves encoding a
genotypic score, sj, for each individual j in the group. An infinite
number of encoding schemes are available. Here we study three
encoding schemes. In the first one, the genotypic score is the sum
of individual genotypes
sj~
X Ln
l~1
gjl,
where Ln is the number of rare non-synonymous variants, and gjl
(0, 1, or 2) is the genotype at the lth variant for the jth individual.
This encoding scheme is also adopted by a recent study [35]. The
second and third schemes involve weighting each variant by its
score simulated in the previous section. Denote, for each variant l,
pl and ol as the continuous and binary functional measures. The
genotypic score is given by
sj~
X Ln
l~1
plgjl
for the second encoding scheme, and is given by
sj~
X Ln
l~1
olgjl
for the third scheme.
The association between the phenotype and encoded genotypic
score is then examined by a logistic regression model. Specifically,
logit(qj)~log
qj
1{qj
~b0zb1Sj,
where qj is the risk of developing the disease for the individual.
Common variants can be analyzed in the combination with
grouped rare variants in the above logistic regression model.
Denote gj~(sj,gj1,:::,gjm)
0
as the vector of the combination of rare
and common variants, where m is the number common variants.
The above logistic regression test is rewritten as
logit(qj)~log
qj
1{qj
~b0zb
0gj:
We denote tests with the three different encoding schemes as
sum test (ST), functional variant weighted continuous sum test
(FWCST) and functional variant weighted binary sum test
(FWBST).
For comparison, we include two extensive tests that involve
grouping rare variants for testing association. The first is the
collapsing and its relevant combined multivariate collapsing
(CMC) tests [15]. In the collapsing method, genotypic score is
an indicator of the presence of rare variants
sj~
1, if rare variants present
0, otherwise
  
:
The association between the disease status and genotypic score is
examined by the Fisher’s exact test or x2 test. When common
Detecting Rare Variants
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of common and grouped rare variants in a multivariate model,
such as Hotelling’s T
2 test [15].
The second test is the group-wise weighted sum statistic
(GWWS) [16]. In GWWS, the genotypic score is another weighted
sum of individual genotypes
sj~
X Ln
l~1
wlgjl:
wl is assigned so that rarer variants get heavier weights, because
rarer variants tend to have a larger effect on phenotype. The
association is examined by a rank-sum statistic, and the
significance is evaluated by permuting and replicating the test k,
e.g., 1000, times.
Evaluating performance
We evaluate statistical properties, including type-I error rates
and power, of various tests by simulation. Type-I error rates are
estimated by setting the locus heritability to zero, and power is
estimated by setting it to a specified proportion, e.g., 0.5%. Both
type-I error rates and power are estimated on 10,000 replicates,
where power is defined as the proportion of replicates in which the
association is detected at the predefined significance level 1.0E-6.
We also study the effects of several influential factors, e.g., the
sensitivity and specificity of predicting algorithms, number of
variants, and proportion of variants, on power estimates. When
evaluating the effect of one particular factor, other parameters will
be fixed at base line values.
Application
As an application, we analyze the sequence data produced by
Cohen et al. [34]. In their study, the authors sequenced three
candidate genes (ABCA1, APOA1, and LCAT) in an initial sample
with two groups of individuals to identify mutations that cause low
high-density lipoprotein cholesterol (HDL-C) levels. The two
groups each comprising 128 individuals were selected from the
upper and lower 5% of the distribution of plasma HDL-C levels in
the Dallas Heart Study (DHS) (Dallas sample). The authors
identified a total number of 29 non-synonymous variants, but only
18 variants that were exclusive to either group were reported. As
in [34], we combined variants of these three genes and analyzed
them together. Two variants, each having four alleles in the 64
black individuals (Bayesian posterior frequency 3.8%), were
considered as common variants, and the other 16 rare variants
were grouped together.
The authors also sequenced the same three genes in a second
sample comprising 155 white Canadians who had low levels of
HDL-C and 108 who had high levels (Canada sample). A total
number of 32 non-synonymous variants were identified, but only 23
variants, which were all rare, were reported and thus were available
for us to analyze.
In their analysis, the authors predicted the impact of each
variant on maintaining protein function using the predicting
algorithm PolyPhen [19]. There are three qualitative measures
available from PolyPhen: ‘‘benign’’, ‘‘possibly damaging protein’’,
and ‘‘probably damaging protein’’. We take ‘‘benign’’ variants as
non-functional, and the other two types as functional. In addition,
a position-specific independent counts (PSIC) profile score [36]
from PolyPhen is available as a quantitative measure for each
variant, which will be used in this study. Non-sense mutations, e.g.,
mutations that truncate proteins, could not be predicted by
PolyPhen. As non-sense mutations probably change protein
function, we category them as functional variants, and assign
them the highest quantitative weight among others.
Results
In this section, we first estimated the demographic model by
analyzing the real sequence dataset produced by the ENOCDE3
project [37]. Based on the inferred demographic model, we then
performed a series of simulation studies to evaluate the
performance of several rare variant aimed association tests,
including the proposed functional variant weighted continuous
sum test (FWCST), binary sum test (FWBST), and sum test
without weighting (ST). Two other existing tests, namely
combined multivariate collapsing test (CMC) [15] and group-wise
weighted sum statistic test (GWWS) [16], were also included in our
analysis for comparison. We finally re-analyzed the real study
reported by Cohen et al. [34].
Estimating demographic model
The four parameters of demographic model estimated by
maximum likelihood estimation are N1=20,000, Nb=14,000,
T=3,300, and c=0.001 (See figure 2 for illustration). N1 and Nb
are larger than a previous report by two fold [38]. Given an
average 20 years per human generation, the estimated T implies
that the bottleneck occurred ,66,000 years ago (66 kya). This
estimation is consistent with the ‘‘out-of-Africa’’ event which
presumes that the European branch was expanded from Africa
,80–40 kya. The estimated effective size of today’s population is
,380,000, much larger than that reported in [38] (20,000), but
smaller than that reported in [14] (900,000). For neutral variants
the estimated allele frequencies from simulations matched quite
well with experimental data (figure 3A). Due to the limited number
of non-synonymous variants in this dataset, the strength of natural
selection could not be evaluated. Instead, using a model with
neutral selection, the frequency predicted by simulation for alleles
in gene coding regions matched quite well with the experimental
data from the ENCODE3 project (figure 3B). This may be
Figure 2. Demographic model. The constant ancestral population
(N1) is followed by a population bottleneck with a reduction of effective
size (Nb), and then by an exponentially expansion with T generations,
until to the present population (Ne).
doi:10.1371/journal.pone.0013857.g002
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limited number of available non-synonymous variants.
Testing association
Type-I error rates. As shown in table 1, all methods have
reasonable type-I error rates that are close to target levels in all
situations that were studied.
Power with proportion of causative variants. All methods
had increased power as the proportion of causative variants
increased; their relative performance depended on the proportion
(figure 4). When the proportion was lower than 0.7, FWCST and
FWBST had the highest power. When the proportion exceeded
0.7, however, the power of ST exceeded that of FWBST. When
the proportion was as high as 0.9, the power of ST exceeded that
of FWCST, and the power of GWWS exceeded that of FWBST.
Comparing FWCST to FWBST, FWBST had higher power when
the proportion was below 0.5 but, at levels above 0.5 FWCST had
higher power. Comparing ST to GWWS, GWWS had higher
power when the proportion was below 0.4 but, at levels above 0.4,
ST had higher power. CMC had the lowest power under all tested
conditions.
Power with predicting sensitivity. The sensitivity of
functional variant prediction is defined as the probability of
correctly identifying a truly functional mutation (Functional
variants are assumed to be causative/relevant to phenotype).
Sensitivity affected the performance of FWCST and FWBST in
that power increased with greater sensitivity (figure 5). The relative
performance of FWCST and FWBST to other tests also depended
on the proportion of causative variants. At low (20%, figure 5A),
medium (50%, figure 5B), and high (80%, figure 5C) proportions,
their power exceeded that of other tests when sensitivity exceeded
approximately 0.4, 0.6, and 0.8, respectively. When sensitivity was
low, FWCST was more powerful than FWBST, but power
increased more rapidly for FWBST than for FWCST with
Figure 3. Fitness of simulated variants to experimental variants. The fitness of allele frequencies simulated by the demographic model to
that of experimental data for neutral variants (A) and coding variants (B).
doi:10.1371/journal.pone.0013857.g003
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FWBST was more powerful than FWCST. Among the other
methods, GWWS and ST had approximately equal power, while
the power of CMC was lowest.
Power with predicting specificity. The specificity of
functional variant prediction is defined as the probability of
incorrectly classifying a non-functional mutation as a functional
one. Specificity affected the performance of FWCST and FWBST
in that power decreased with increasing specificity (figure 6).
Again, the relative performance among tests depended on the
proportion of causative variants. At low proportion (figure 6A), the
power of FWCST and FWBST was higher when specificity was
lower than ,0.6. At medium and high proportions (figure 6B&C),
the specificity criteria for power improvement was around 0.5 and
0.3, respectively. GWWS and ST had approximately equal power,
while that of CMC was lowest.
Power with effective proportion of causative variants.
Since FWCST and FWBST improved power by increasing the
effective proportion of causative variants, it is of interest to
evaluate their performance when the effective proportion after
weighting remains equal to that without weighting. This could
occur when the information available does not facilitate selection
of true functional variants. To remain the effective proportion
equal to that without weighting, the sensitivity and specificity have
to be equal (see the Discussion section for the derivation). It was
clear that both FWCST and FWBST had lower power than ST
(figure 7), implying that uninformative weighting schemes would
cause a loss of power. The power of both tests increased with
increasing sensitivity. Finally when sensitivity reached 1.0,
FWBST was equivalent to ST, but FWCST was still inferior to
ST. The power loss was more severe for FWBST than for FWCST
in most cases.
Power with gene length. Gene length affected the
performance of different tests quite differently (figure 8). For
FWCST and FWBST, power increased with increasing gene
length, though the magnitude of this change was minor. For the
other tests, however, power decreased with increasing gene length.
The power loss was much more severe for CMC than for ST and
GWWS. Comparing the two functional variant weighted tests,
FWBST was more powerful at low proportion (figure 8A), but had
approximately equal power to that FWCST had at the other two
proportions (figure 8B and 8C). At low and medium proportions,
FWBST and FWCST were most powerful, followed by ST and
GWWS, which had approximately equal power, and then by
CMC, which had the lowest power. At the high proportion, while
all other tests maintained power at high levels, the power of CMC
decreased substantially with increasing gene length.
Power with gene effect. The power of all methods increased
with increasing locus heritability (figure 9). Among the tests,
FWCST and FWBST were most powerful, followed by GWWS,
ST, and CMC. At a low proportion of causative variants
(figure 9A), FWCST, FWBST, and GWWS had the ability to
Table 1. Type I error rates.
Sequenced Nominal level
sample Gene 5% 1%
size length FWCST FWBST ST GWWS CMC FWCST FWBST ST GWWS CMC
1,000
500 5.6 5.5 5.0 5.1 4.7 1.2 1.1 0.8 1.0 1.2
1,000 5.1 5.5 4.9 5.1 5.2 1.2 1.1 1.1 1.0 1.1
1,500 5.5 5.3 5.4 5.1 5.5 1.1 1.3 1.2 1.2 1.3
2,000 4.8 5.1 4.8 4.9 4.5 0.9 0.7 1.2 0.9 1.0
2,500 5.2 4.7 4.9 4.9 4.7 1.2 1.2 1.1 1.0 0.8
3,000 4.7 5.4 4.9 4.8 5.5 1.1 1.2 0.8 0.9 1.3
2,000
500 5.5 5.7 5.1 5.0 5.3 1.0 1.1 0.9 1.0 0.8
1,000 4.8 4.5 5.1 4.7 4.8 1.0 1.1 0.8 0.9 0.9
1,500 4.2 5.0 4.5 4.5 5.0 0.8 0.9 0.9 1.0 1.0
2,000 4.5 4.3 5.2 5.4 5.5 0.8 1.0 1.0 1.4 1.5
2,500 4.8 4.3 5.3 5.5 5.1 0.8 0.8 1.2 1.1 1.2
3,000 5.0 4.7 4.4 4.2 5.4 1.1 1.2 0.9 1.1 1.1
4,000
500 5.2 5.3 5.1 5.2 4.7 1.1 1.0 1.2 1.0 1.2
1,000 5.5 5.2 5.0 4.8 4.9 1.1 1.1 0.9 0.8 1.0
1,500 5.4 5.1 5.1 5.1 5.2 1.0 1.2 0.9 1.2 0.9
2,000 4.6 4.8 4.5 4.8 4.5 0.8 1.0 0.8 0.8 1.0
2,500 5.5 5.5 5.3 5.1 5.1 1.0 1.2 1.0 1.0 1.1
3,000 4.9 5.0 4.4 4.5 4.5 0.8 0.7 0.8 0.8 0.8
Sequenced sample size varies from 1,000 to 4,000, while the gene length varies from 500 to 3,000 nucleotides. Type I error rate is estimated on 10,000 replicates at
significance levels 5% and 1%.
Abbreviation: FWCST, the proposed functional variant weighted continuous sum test; FWBST, the proposed functional variant weighted binary sum test; ST, the sum
test without weighting; GWWS, the group-wise weighted sum test [16]; CMC, the combined multivariate collapsing test [15].
doi:10.1371/journal.pone.0013857.t001
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For ST and CMC, at a low proportion of causative variants, 100%
power was achieved at heritability levels of 2.0 and 3.0%,
respectively. At high proportions (figure 9C), all tests had nearly
100% power to detect genes with heritability of 1.0% or more, and
similar results were obtained at medium proportions (figure 9B)
with all tests except CMC, which did not achieve 100% power
until heritability reached 1.5%.
Power with phenotyped and sequenced sample size.
Since we simulated a large pool of phenotyped individuals and
selected individuals with extreme phenotypes from the pool for
sequencing, we investigated the effect of the number of phenotyped
andsequencedindividualsonpowerestimation.Asshownintable2,
sequencing greater numbers of individuals certainly increased
power for all tests, as did increasing the pool of phenotyped
individuals. When sequencing 2,000 individuals from a pool of
50,000 phenotyped individuals, the power of FWCST and FWBST
was 81% and 87%, respectively, for detecting a gene with 1,500
nucleotides. When the number of phenotyped individuals increased
to 100,000, the power of FWCST and FWBST increased to 90%
and 92%, respectively, without additional sequencing cost.
Comparing the tests, the power of FWCST and FWBST was
highest, followed by ST, GWWS, and CMC.
Application
In order to verify the results of our simulation studies, we
analyzed the sequence dataset produced by Cohen et al. [34].
When applied to the Dallas sample, FWCST and FWBST had p-
values of 4.03E-4 and 4.41E-4, which were higher than that of ST
(2.46E-4) and GWWS (7.71E-5), but lower than that of CMC
(1.17E-3) (table 3). The inferior performance of FWCST and
FWBST compared to ST and GWWS was caused by the fact that
of the 3 variants that were exclusive in the control group (high
HDL-C), two were predicted to be ‘‘damaging protein’’, resulting
in a specificity rate as high as 0.7. However, this comparison
probably created an advantage for un-weighted tests because
another 11 variants, that were present in both case and control
groups, were not included in the authors’ analysis. If these
variants, which were likely to be neutral, had been included, the
specificity of prediction would be expected to decrease, thereby the
relative performance of FWCST and FWBST compared to other
tests would be improved.
When applied to the Canada sample, both FWCST and
FWBST produced lower p-values (thus likely higher power)
(1.97E-4 and 1.46E-5) than those of other tests (ST: 1.35E-3;
GWWS: 1.81E-3; CMC: 2.74E-3). In this sample, both variants
exclusive to the control group were predicted to be neutral,
Figure 4. Power with proportion of causative variants. Genotype data of a gene with 1,500 nucleotides are simulated. A pool of 50,000
quantitatively phenotyped individuals is generated, from which 1,000/1,000 individuals with the lowest and highest phenotypes are selected and
labeled as control/case subjects. Causative variants explain cumulatively 0.5% of the total phenotypic variation, of which 90% is explained by rare
variants, and the remaining 10% by common variants. The sensitivity and specificity of prediction algorithms are set to 0.8 and 0.15, respectively.
Power is estimated on 10,000 replicates, defined as the proportion of replicates in which the gene is detected at the significance level 1.0E-6.
Abbreviation: FWCST, the proposed functional variant weighted continuous sum test; FWBST, the proposed functional variant weighted binary sum
test; ST, the sum test without weighting; GWWS, the group-wise weighted sum test [16]; CMC, the combined multivariate collapsing test [15].
doi:10.1371/journal.pone.0013857.g004
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and 80% (C). The specificity for identifying functional variants is set to 0.15. See the legend for figure 4 for abbreviations and simulation detail.
doi:10.1371/journal.pone.0013857.g005
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legend for figure 4 for abbreviations and simulation detail.
doi:10.1371/journal.pone.0013857.g006
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PLoS ONE | www.plosone.org 9 November 2010 | Volume 5 | Issue 11 | e13857Figure7. Power with equaling effective proportion ofcausative variants. The sensitivity and specificity are set to beequal, in order toretain the
effective proportion of causative variants after weighting to that without weighting. See the legend for figure 4 for abbreviations and simulation detail.
doi:10.1371/journal.pone.0013857.g007
Detecting Rare Variants
PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e13857Figure 8. Power with gene length. Gene length varies from 500 to 3,000 nucleotides, corresponding to a protein length of 170 to 1,000 amino
acids. See the legend for figure 4 for abbreviations and simulation details.
doi:10.1371/journal.pone.0013857.g008
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PLoS ONE | www.plosone.org 11 November 2010 | Volume 5 | Issue 11 | e13857Figure 9. Power with gene effect. Locus heritability varies from 0% to 3%. See the legend for figure 4 for abbreviations and simulation detail.
doi:10.1371/journal.pone.0013857.g009
Detecting Rare Variants
PLoS ONE | www.plosone.org 12 November 2010 | Volume 5 | Issue 11 | e13857resulting in a specificity rate as low as zero. Again, the comparison
would be fairer if the additional 9 variants, that were present in
both case and control groups, had been included for analysis.
Discussion
In this study, we have proposed and evaluated a novel method
to test the association between disease and variants in gene coding
regions. Specifically, we incorporated information generated by
extensive use of predicting algorithms into group-wise association
tests. This was done in order to improve the power of these tests by
distinguishing potential causative variants from background
neutral variation. We also studied the effects of several influential
factors on the performance of the proposed tests. Simulation
studies showed that the use of predicting algorithms to identify
potentially functional variants improves statistical power under
certain conditions, especially when the proportion of functional
variants is moderate. Application of the proposed tests to a real
sequencing study confirmed the results of our simulation studies.
Association, referring to the correlation between phenotype and
genetic variants, can be categorized into indirect and direct
associations. With indirect association, the genetic variants to be
examined are usually neutral bio-markers, e.g., SNPs, while the
causative variants are untyped. In order for indirect association
studies to be effective, there must be linkage disequilibrium (LD;
i.e., nonrandom association), between these neutral bio-markers
and the causative variants. Variant alleles in indirect association
usually have no functional biological impact, and are often
encoded as 1 or 0 to indicate the presence or absence of a
particular allele. With direct association, in contrast, the variants
that are examined are assumed to be functional, and not only the
presence or absence of a particular allele but also its type (e.g., A,
G, C, or T) is informative. This distinction has made analytical
approaches for sequencing-based direct association studies differ-
ent from those used for genotyping-based indirect association
studies.
Sequencing genomic regions identifies a greater number of rare
variants than that identified by genotyping platforms. The
challenge in analyzing rare variants is attributable both to their
rarity, and to the fact that a large proportion of these rare variants
represent background population variation with no functional
impact. While grouping strategies could enlarge mutation signals,
the anticipated excess number of neutral variants within the group
would decrease signal-to-noise ratios to very low levels. Therefore,
it would be highly advantageous to differentiate potential causative
variants from neutral ones, prior to association analyses, with the
goal of increasing signal-to-noise ratios.
In gene coding regions, the functional impact of a variant can be
predicted from protein structure and function, and multiple
sequence alignments. Functional variants predicted by existing
algorithms distribute differently between disease-affected and
normal populations. For example, when applied to a disease-
causing mutation database annotated in SwissProt, PolyPhen
predicts that ,82% of all mutations will result in damaged protein
[19]. When applied to a control set of between-species
substitutions, however, only ,8% of mutations fall into this
category [19]. Several recent sequencing studies provide additional
evidence for this relationship between predicted functional
variants and phenotype [30,33,34,39]. For example, in the study
of Cohen et al. [34], 17 of 25 non-synonymous SNPs (nsSNPs)
identified in the ABCA1 gene in case group are predicted to be
‘‘damaging protein’’. Given PolyPhen’s false positive rate on
neutral substitutions being 0.08, the p-value for observing this data
from a binomial distribution is as low as 1.30E-13. Similar analysis
on nsSNPs in control group (2 of 4 being ‘‘damaging protein’’)
presents a much higher p-value 0.03 [27]. Therefore, predicted
functional variants are highly correlated with disease phenotype,
which justifies the importance and attests to the feasibility of
identifying putative functional variants prior to grouped associa-
tion analyses.
A variety of algorithms have been proposed to predict the
functional impact of amino acid substitutions [18,19,20,21,22,23,
24,25,26,40]. Prediction could be based on multiple ortholog
sequences, proteinstructures,andannotation ofvariants.Inourreal
data analysis, we used PolyPhen [19] which uses sequence-,
structure-, and annotation-based information as input. The benefits
of using these prediction algorithms are dependent on the capacity
to increase the effective proportion of causative variants, which is
highly dependent on the sensitivity and specificity of the algorithm
used. For a particular sample with N variants, let f represent the
Table 2. Power with phenotyped and sequenced sample
sizes.
Phenotyped Sequenced Tests
sample size sample size FWCST FWBST ST GWWS CMC
25,000
1,000 0.29 0.41 0.05 0.06 0.01
2,000 0.57 0.70 0.16 0.17 0.06
4,000 0.76 0.84 0.27 0.29 0.10
50,000
1,000 0.44 0.59 0.09 0.11 0.02
2,000 0.81 0.87 0.30 0.34 0.10
4,000 0.95 0.96 0.64 0.69 0.30
100,000
1,000 0.60 0.72 0.15 0.20 0.04
2,000 0.90 0.92 0.49 0.59 0.20
4,000 0.99 0.99 0.84 0.91 0.51
The pool of phenotyped individuals with varies sizes is generated. For each
pool, equal numbers of individuals with the lowest and highest phenotypes are
selected for sequencing. A gene with 1,500 nucleotides is simulated. Power is
estimated on 10,000 replicates at the significance level 1.0E-6.
doi:10.1371/journal.pone.0013857.t002
Table 3. Analyses of the real sequence data.
Tests p-value
Dallas Canada
FWCST 4.03E-4 1.97E-4
FWBST 4.41E-4 1.46E-5
ST 2.46E-4 1.35E-3
GWWS 7.71E-5 1.81E-3
CMC 1.17E-3 2.74E-3
In the Dallas sample, three genes (ABCA1, APOA1,a n dLCAT) were sequenced in
two groups, each of which contained 128 individuals. A total of 29 non-
synonymous variants were identified, but only 18 variants were available for
analysis. 16 of these 18 variants were exclusive to the case group, and the
remaining 2 were exclusive to the control group. In the Canada sample, the
same three genes were sequenced in two groups containing 155 and 108
individuals. Of the 23 variants that were available for analysis, 21 were exclusive
to the case group and the remaining 2 were exclusive to the control group.
doi:10.1371/journal.pone.0013857.t003
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sensitivity and specificity of a particular predicting algorithm. The
effective numbers of causative and neutral variants after weighting
are thus bfN and a(1{f)N, respectively, so that the effective
proportion of causative variants after weighting is
bfN
bfNza(1{f)N
.
When b.a, it is clear that the effective proportion will be larger
than f, and the proposed tests tend to be more powerful. In contrast,
the effective number of causative variants decreases from fN to
b:fN, thereby reducing power. Therefore, the relative performance
of weighted tests reflects the balance of these two opposite effects.
When b=a, the effective proportion remains f, but the effective
number is still reduced to b:fN. This leads to reduced power, where
the power loss gets less severe with increasing b, as shown by our
simulations. For a particular b, the loss of power is influenced by the
diversityof weights being assigned.Forthe binary weightingscheme
FWBST where extreme weights (1 or 0) are assigned, power loss is
severe. For the continuous weighting scheme, FWCST, where
intermediate continuous weights (between 0 and 1) are assigned,
power loss gets less severe.
Weighting variants within a group has been proposed by Madsen
& Browning [16], however, their weighting scheme is derived from
the sample that is being studied. Specifically, they assigned heavier
weights to rarer variants in the control population. The merit of
their method relies heavily on the assumption that rarer variants
have larger per-allele effects. Violation of this assumption, as
observed in the simulations used in this study, would diminish the
advantages of their test. In our simulations, GWWS had a greater
power than ST, without weighting, only when the proportion of
causative variants was low; otherwise, ST actually had a slightly
greater power. When prior knowledge that is independent of the
sample under investigation is available, GWWS could be inferior to
the proposed functional variant weighted tests. Another assump-
tion-related observation is that CMC is generally inferior to the
other tests. This observation depends on the underlying biological
mechanism for the phenotype. In CMC, individuals with one or
more mutations are encoded with the same genetic score.
Corresponding to the underlying mechanism of gene expression,
it assumes that any single mutation will cause complete loss of
protein function, which probably only occurs for non-sense
mutations. In our simulations, however, mutations affect phenotype
in a cumulative way such that each mutation causes only a partial
loss of protein function. This critical difference between their
assumption and our simulations may account for the inferior
performance of CMC in this study.
Weighting variants based on prior information has also been a
research focus for years in common variants based association
studies [41,42,43,44]. Among previous studies, Genovese et al.
[42] proposed a general framework that incorporated prior
information into genome-wide association studies (GWAS) to
overcome the problem of multiple hypothesis testing. In brief, they
assigned each SNP a weight so that SNPs with heavier weights
were penalized less when using multiple testing corrections.
Following their work, Roeder et al. [43] proposed formulating
weights based on previous linkage traces. They divided association
p-values by weights that were predefined, and applied the
traditional FDR procedure to the weighted p-values. Roeder et
al. [44] also proposed a weighted multiple testing procedure. Later
work proposed by Chen and Witte [41] incorporated various
sources of prior information, such as linkage signal, functional
category, conservation, and LD, into a Bayesian hierarchical
model to reflect the prior likelihood of the SNP being associated.
All of these methods were shown to have the ability to improve
power of detecting the association assuming that the prior
information was correctly specified.
Rare and common variants aimed weightings share, in
common, the idea of using prior information to improve power,
however they are different in the following aspects. First, common
variants are tested individually, and weighting operates on the
resulting individual p-values, while rare variants are tested
together and weighting operates on individual genotypes. Second,
the aim of weighting for common variants is to relieve the problem
of multiple hypotheses testing by punishing different tests
differently through the weights they are assigned. In contrast the
aim of weighting for rare variants is to improve the effective
proportion of causative variants within group. Hence, largely
speaking, the general goal and detailed specific strategies involved
are largely different in rare and common variants aimed
weightings.
In this study, we restrict our attention to non-synonymous
variants in gene coding regions because these variants have direct
functional implications. In principal, the weighting scheme could
also be extended to variants in other genomic regions, e.g., gene
introns, regulatory regions (enhancer, silencer, and etc.), splicing
sites, and ultra-conserved regions, by studying ortholog sequences
between and/or within species. However, caution should be taken
when studying these non-coding variants, because they have no
direct functional meaning in terms of affecting gene expression,
and the relationship between their conservation and phenotype
may not be well established. A study reported by Ahituv et al. [45]
showed that after deleting four non-coding ultra-conserved
elements from the mouse genome, the mice remained viable and
fertile, and revealed no abnormalities for a variety of phenotypes
that were studied. The effects of these conservative genomic
regions in maintaining the normality of species is still being
debated, and whether they can be used to direct the selection of
causative variants may warrant further consideration. Focusing
analyses on gene-coding regions provides a plausible trade-off
between sequencing cost and discovery of informative variants,
and may be an attractive study design before genome-wide
sequencing study becomes widely available [14,30,46,47,48].
In conclusion, we propose that the use of predicting algorithms
to distinguish causative variants from background population
variation, and incorporation of this information into association
tests, can improve statistical power for detecting rare variants that
are associated with diseases. This conclusion is supported by both
simulation studies and the application of this approach to real
sequencing data. Our work may help investigators who are
planning to pursue large-scale gene based sequencing studies.
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